ADA and combined immunodeficiency: The trial involvedtreatment of two patients with severe combined immunodeficiency caused by the deficiencyof adenosine deaminase (SCID-ADA).9 Since then,2,597 trials had been approved worldwide, up to 2019, according to the website.10